The New Direct Oral Anticoagulants in Special Indications: Rationale and Preliminary Data in Cancer, Mechanical Heart Valves, Anti-phospholipid Syndrome, and Heparin-Induced Thrombocytopenia and Beyond

Seminars in Hematology

Volumn 51, Issue 2, 2014, Pages 152-156

  Alberio, Lorenzo ^a  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; ANTIVITAMIN K; APIXABAN; BLOOD CLOTTING FACTOR 10A; DALTEPARIN; HEPARIN; HEPARIN DERIVATIVE; LOW MOLECULAR WEIGHT HEPARIN; RIVAROXABAN; THROMBIN;

ANTICOAGULANT THERAPY; ANTIPHOSPHOLIPID SYNDROME; ARTICLE; BLEEDING; BLOOD CLOTTING; CANCER RECURRENCE; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG EFFICACY; DRUG INDICATION; DRUG MECHANISM; FIBRINOLYSIS; GASTROINTESTINAL HEMORRHAGE; HEPARIN INDUCED THROMBOCYTOPENIA; HUMAN; INFLAMMATION; INTERNATIONAL NORMALIZED RATIO; KIDNEY FAILURE; MALIGNANT NEOPLASTIC DISEASE; MECHANICAL HEART VALVE; PRIORITY JOURNAL; RECURRENT DISEASE; TREATMENT RESPONSE; VENOUS THROMBOEMBOLISM;

ADMINISTRATION, ORAL; ANIMALS; ANTICOAGULANTS; ANTIPHOSPHOLIPID SYNDROME; HEART VALVE DISEASES; HEPARIN; HUMANS; NEOPLASMS; THROMBOCYTOPENIA; VENOUS THROMBOEMBOLISM;

EID: 84901368918     PISSN: 00371963     EISSN: 15328686     Source Type: Journal    
DOI: 10.1053/j.seminhematol.2014.03.002     Document Type: Article

References (51)

1. Esmon C.T. The interactions between inflammation and coagulation. Br J Haematol 2005, 131:17-430.
2. Levi M. The coagulant response in sepsis and inflammation. Hamostaseologie 2010, 30(10-2):14-16.
3. Borensztajn K., Peppelenbosch M.P., Spek C.A. Factor Xa: at the crossroads between coagulation and signaling in physiology and disease. Trends Mol Med 2008, 14:429-440.
4. Coughlin S.R. Thrombin signalling and protease-activated receptors. Nature 2000, 407:258-264.
5. Lee I.O., Kratz M.T., Schirmer S.H., Baumhakel M., Bohm M. The effects of direct thrombin inhibition with dabigatran on plaque formation and endothelial function in apolipoprotein E-deficient mice. J Pharmacol Exp Ther 2012, 343:253-257.
6. Kadoglou N.P., Moustardas P., Katsimpoulas M., et al. The beneficial effects of a direct thrombin inhibitor, dabigatran etexilate, on the development and stability of atherosclerotic lesions in apolipoprotein E-deficient mice: dabigatran etexilate and atherosclerosis. Cardiovasc Drugs Ther 2012, 26:367-374.
7. Zhou Q., Bea F., Preusch M., et al. Evaluation of plaque stability of advanced atherosclerotic lesions in apo E-deficient mice after treatment with the oral factor Xa inhibitor rivaroxaban. Mediators Inflamm 2011, 2011:432080.
8. Chan M.Y., Lin M., Lucas J., et al. Plasma proteomics of patients with non-valvular atrial fibrillation on chronic anti-coagulation with warfarin or a direct factor Xa inhibitor. Thromb Haemost 2012, 108:1180-1191.
9. Vincent J.L., Ramesh M.K., Ernest D., et al. A randomized, double-blind, placebo-controlled, Phase 2b study to evaluate the safety and efficacy of recombinant human soluble thrombomodulin, ART-123, in patients with sepsis and suspected disseminated intravascular coagulation. Crit Care Med 2013, 41:2069-2079.
10. Esmon C. Targeting factor Xa and thrombin: impact on coagulation and beyond. Thromb Haemost 2013, 111.
11. Spronk H.M., de Jong A.M., Crijns H.J., Schotten U., Van Gelder I.C., Ten Cate H. Pleiotropic effects of factor Xa and thrombin: what to expect from novel anticoagulants. Cardiovasc Res 2014, 101:344-351.
12. Farge D., Debourdeau P., Beckers M., et al. International clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer. J Thromb Haemost 2013, 11:56-70.
13. Lee A.Y., Peterson E.A. Treatment of cancer-associated thrombosis. Blood 2013, 122:2310-2317.
14. Meyer G., Marjanovic Z., Valcke J., et al. Comparison of low-molecular-weight heparin and warfarin for the secondary prevention of venous thromboembolism in patients with cancer: a randomized controlled study. Arch Intern Med 2002, 162(15):1729-1735.
15. Lee A.Y., Levine M.N., Baker R.I., et al. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med 2003, 349:146-153.
16. Wharin C., Tagalakis V. Management of venous thromboembolism in cancer patients and the role of the new oral anticoagulants. Blood Rev 2014, 28:1-8.
17. Schulman S., Kearon C., Kakkar A.K., et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med 2009, 361:2342-2352.
18. Schulman S., Kearon C., Kakkar A.K., et al. Extended use of dabigatran, warfarin, or placebo in venous thromboembolism. N Engl J Med 2013, 368:709-718.
19. Bauersachs R., Berkowitz S.D., Brenner B., et al. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med 2010, 363:2499-2510.
20. Buller H.R., Prins M.H., Lensin A.W., et al. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med 2012, 366:1287-1297.
21. Agnelli G., Buller H.R., Cohen A., et al. Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med 2013, 369:799-808.
22. Buller H.R., Decousus H., Grosso M.A., et al. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. N Engl J Med 2013, 369:1406-1415.
23. van Doormaal F.F., Raskob G.E., Davidson B.L., et al. Treatment of venous thromboembolism in patients with cancer: subgroup analysis of the Matisse clinical trials. Thromb Haemost 2009, 101:762-769.
24. Cohen A.T., Spiro T.E., Buller H.R., et al. Rivaroxaban for thromboprophylaxis in acutely ill medical patients. N Engl J Med 2013, 368:513-523.
25. Carrier M., Khorana A.A., Zwicker J., Noble S., Lee A.Y. Management of challenging cases of patients with cancerassociated thrombosis including recurrent thrombosis and bleeding: guidance from the SSC of the ISTH. J Thromb Haemost 2013, 11:1760-1765.
26. Schulman S., Crowther M.A. How I treat with anticoagulants in 2012: new and old anticoagulants, and when and how to switch. Blood 2012, 119:3016-3023.
27. Lazo-Langner A., Goss G.D., Spaans J.N., Rodger M.A. The effect of low-molecular-weight heparin on cancer survival. A systematic review and meta-analysis of randomized trials. J Thromb Haemost 2007, 5:729-737.
28. Kuderer N.M., Khorana A.A., Lyman G.H., Francis C.W. A meta-analysis and systematic review of the efficacy and safety of anticoagulants as cancer treatment: impact on survival and bleeding complications. Cancer 2007, 110:1149-1161.
29. Akl E.A., Gunukula S., Barba M., et al. Parenteral anticoagulation in patients with cancer who have no therapeutic or prophylactic indication for anticoagulation. Cochrane Database Syst Rev 2011, (CD006652).
30. Mousa S.A., Petersen L.J. Anti-cancer properties of low-molecular-weight heparin: preclinical evidence. Thromb Haemost 2009, 102:258-267.
31. Borsig L. Antimetastatic activities of heparins and modified heparins. Experimental evidence. Thromb Res 2010, 125(Suppl 2):S66-S71.
32. Yavuz C., Caliskan A., Karahan O., et al. Investigation of the antiangiogenic behaviors of rivaroxaban and low molecular weight heparins. Blood Coagul Fibrinolysis 2013, [PMID:24256628]. Epub ahead of print. DOI:10.1097/MBC.0000000000000019.
33. Lee A.Y., Bauersachs R., Janas M.S., et al. CATCH: a randomised clinical trial comparing long-term tinzaparin versus warfarin for treatment of acute venous thromboembolism in cancer patients. BMC Cancer 2013, 13:284.
34. Eikelboom J.W., Connolly S.J., Brueckmann M., et al. Dabigatran versus warfarin in patients with mechanical heart valves. N Engl J Med 2013, 369:1206-1214.
35. Dewanjee M.K., Gross D.R., Zhai P., et al. Thrombogenicity of polyethylene oxide-bonded Dacron sewing ring in a mechanical heart valve. J Heart Valve Dis 1999, 8:324-330.
36. Kalicki R.M., Aregger F., Alberio L., Lämmle B., Frey F.J., Uehlinger D.E. Use of the pentasaccharide fondaparinux as an anticoagulant during haemodialysis. Thromb Haemost 2007, 98:1200-1207.
37. Mann K.G., Brummel K., Butenas S. What is all that thrombin for?. J Thromb Haemost 2003, 1:1504-1514.
38. Ansell J. Factor Xa or thrombin: is factor Xa a better target?. J Thromb Haemost 2007, 5(Suppl 1):60-64.
39. Greiten L.E., McKellar S.H., Rysavy J., Schaff H.V. Effectiveness of rivaroxaban for thromboprophylaxis of prosthetic heart valves in a porcine heterotopic valve model. Eur J Cardiothorac Surg 2013, [PMID: 24306948]. Epub ahead of print. DOI: 10.1093/ejcts/ezt545.
40. Mueck W., Borris L.C., Dahl O.E., et al. Population pharmacokinetics and pharmacodynamics of once- and twice-daily rivaroxaban for the prevention of venous thromboembolism in patients undergoing total hip replacement. Thromb Haemost 2008, 100:453-461.
41. Kaeberich A., Reindl I., Raaz U., et al. Comparison of unfractionated heparin, low-molecular-weight heparin, low-dose and high-dose rivaroxaban in preventing thrombus formation on mechanical heart valves: results of an in vitro study. J Thromb Thrombolysis 2011, 32:417-425.
42. Rombouts E.K., Rosendaal F.R., van der Meer F.J. Subtherapeutic oral anticoagulant therapy: frequency and risk factors. Thromb Haemost 2009, 101:552-556.
43. Kubitza D., Becka M., Wensing G., Voith B., Zuehlsdorf M. Safety, pharmacodynamics, and pharmacokinetics of BAY 59-7939-an oral, direct Factor Xa inhibitor--after multiple dosing in healthy male subjects. Eur J Clin Pharmacol 2005, 61:873-880.
44. Erkan D., Aguiar C.L., Andrade D., et al. 14th International Congress on Antiphospholipid Antibodies Task Force Report on Antiphospholipid Syndrome Treatment Trends. Autoimmun Rev 2014, Epub ahead of print. DOI: 10.1016/j.autrev.2014.01.053.
45. Nellen V., Sulzer I., Barizzi G., Lämmle B., Alberio L. Rapid exclusion or confirmation of heparin-induced thrombocytopenia: a single-center experience with 1,291 patients. Haematologica 2012, 97:89-97.
46. Tschudi M., Lämmle B., Alberio L. Dosing lepirudin in patients with heparin-induced thrombocytopenia and normal or impaired renal function: a single-center experience with 68 patients. Blood 2009, 113:2402-2409.
47. Warkentin T.E., Greinacher A., Koster A. Bivalirudin. Thromb Haemost 2008, 99:830-839.
48. Alatri A., Armstrong A.E., Greinacher A., et al. Results of a consensus meeting on the use of argatroban in patients with heparin-induced thrombocytopenia requiring antithrombotic therapy - a European Perspective. Thromb Res 2012, 129:426-433.
49. Bakchoul T., Greinacher A. Recent advances in the diagnosis and treatment of heparin-induced thrombocytopenia. Ther Adv Hematol 2012, 3:237-251.
50. Krauel K., Hackbarth C., Furll B., Greinacher A. Heparin-induced thrombocytopenia: in vitro studies on the interaction of dabigatran, rivaroxaban, and low-sulfated heparin, with platelet factor 4 and anti-PF4/heparin antibodies. Blood 2012, 119:1248-1255.
51. Linkins L.A., Warkentin T.E., Pai M., et al. Design of the rivaroxaban for heparin-induced thrombocytopenia study. J Thromb Thrombolysis 2014, [PMID:24549975]. Epub ahead of print. DOI: 10.1007/s11239-014-1064-7.